Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies | Zendy

Michel Aubier | Zendy; H. Lode | Zendy; G Gialdroni-Grassi | Zendy; G Huchon | Zendy; J. Hosie | Zendy; N.J. Legakis | Zendy; C Regamey | Zendy; Shlomo Segev | Zendy; Rasmus Mølgård Vester | Zendy; W. J. A. Wijnands | Zendy; N. Tolstuchow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies

Author(s) -

Michel Aubier,

H. Lode,

G Gialdroni-Grassi,

G Huchon,

J. Hosie,

N.J. Legakis,

C Regamey,

Shlomo Segev,

Rasmus Mølgård Vester,

W. J. A. Wijnands,

N. Tolstuchow

Publication year - 1996

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/37.suppl_a.73

Subject(s) - sparfloxacin , medicine , pneumonia , community acquired pneumonia , erythromycin , amoxicillin , antibacterial agent , lomefloxacin , clavulanic acid , dose , antibiotics , ofloxacin , microbiology and biotechnology , ciprofloxacin , biology

A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research